D/2 predictors of favorable outcome in cancer

Z. Pós, Jérôme Galon

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

Prediction of disease outcome in cancer is usually achieved by histological evaluation of tissue samples obtained during surgical extirpation of the primary tumor, mostly focusing on histological characteristics of cancer cells in the tumor mass, such as the extent of atypical cell morphology, of tissue integrity, aberrant expression of protein markers or malignant transformation, senescence and proliferation, various characteristics of the invasive margin and surrounding tumor stroma, depth of invasion, and the extent of vascularization. In addition, histological or radiological analysis of both tumor draining- and distant lymph nodes and remote organs can be carried out looking for evidence of metastases. Based on these data, evaluation of cancer progression can be performed and serve as an estimate of patient prognosis. This is done on the basis of statistical data available of patients exhibiting similar progression characteristics and their actual outcome parameters, such as average disease-free (DFS), disease-specific (DSS) and overall survival (OS). To this end, several dozens of tumor-type specific staging and grading systems have been developed such as Clark's and Breslow's indexes for melanoma, Gleason's score for prostate cancer, Duke's for colorectal cancer, Boden-Gibb's staging for testicular cancer, the Evans staging system for neuroblastoma, etc., and also more universal ones such as the TNM system, which summarizes data on tumor burden (T), presence of cancer cells in draining and distant lymph nodes (N) and evidence for metastases (M). With the large body of statistical data available on cancer patients' survival with a given progression stage, such approaches have been shown to be valuable and in many cases of acceptable accuracy in estimating disease outcome in cancer.

Original languageEnglish
Title of host publicationImmunologic Signatures of Rejection
PublisherSpringer New York
Pages199-210
Number of pages12
ISBN (Print)9781441972194, 9781441972187
DOIs
Publication statusPublished - 2011

Fingerprint

Neoplasms
Neoplasm Grading
Neoplasm Staging
Lymph Nodes
Neoplasm Metastasis
Choristoma
Survival
Testicular Neoplasms
Tumor Burden
Neuroblastoma
Colorectal Neoplasms
Melanoma
Prostatic Neoplasms
Proteins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pós, Z., & Galon, J. (2011). D/2 predictors of favorable outcome in cancer. In Immunologic Signatures of Rejection (pp. 199-210). Springer New York. https://doi.org/10.1007/978-1-4419-7219-4_13

D/2 predictors of favorable outcome in cancer. / Pós, Z.; Galon, Jérôme.

Immunologic Signatures of Rejection. Springer New York, 2011. p. 199-210.

Research output: Chapter in Book/Report/Conference proceedingChapter

Pós, Z & Galon, J 2011, D/2 predictors of favorable outcome in cancer. in Immunologic Signatures of Rejection. Springer New York, pp. 199-210. https://doi.org/10.1007/978-1-4419-7219-4_13
Pós Z, Galon J. D/2 predictors of favorable outcome in cancer. In Immunologic Signatures of Rejection. Springer New York. 2011. p. 199-210 https://doi.org/10.1007/978-1-4419-7219-4_13
Pós, Z. ; Galon, Jérôme. / D/2 predictors of favorable outcome in cancer. Immunologic Signatures of Rejection. Springer New York, 2011. pp. 199-210
@inbook{251af2340c0e4845bf3739c871e5715d,
title = "D/2 predictors of favorable outcome in cancer",
abstract = "Prediction of disease outcome in cancer is usually achieved by histological evaluation of tissue samples obtained during surgical extirpation of the primary tumor, mostly focusing on histological characteristics of cancer cells in the tumor mass, such as the extent of atypical cell morphology, of tissue integrity, aberrant expression of protein markers or malignant transformation, senescence and proliferation, various characteristics of the invasive margin and surrounding tumor stroma, depth of invasion, and the extent of vascularization. In addition, histological or radiological analysis of both tumor draining- and distant lymph nodes and remote organs can be carried out looking for evidence of metastases. Based on these data, evaluation of cancer progression can be performed and serve as an estimate of patient prognosis. This is done on the basis of statistical data available of patients exhibiting similar progression characteristics and their actual outcome parameters, such as average disease-free (DFS), disease-specific (DSS) and overall survival (OS). To this end, several dozens of tumor-type specific staging and grading systems have been developed such as Clark's and Breslow's indexes for melanoma, Gleason's score for prostate cancer, Duke's for colorectal cancer, Boden-Gibb's staging for testicular cancer, the Evans staging system for neuroblastoma, etc., and also more universal ones such as the TNM system, which summarizes data on tumor burden (T), presence of cancer cells in draining and distant lymph nodes (N) and evidence for metastases (M). With the large body of statistical data available on cancer patients' survival with a given progression stage, such approaches have been shown to be valuable and in many cases of acceptable accuracy in estimating disease outcome in cancer.",
author = "Z. P{\'o}s and J{\'e}r{\^o}me Galon",
year = "2011",
doi = "10.1007/978-1-4419-7219-4_13",
language = "English",
isbn = "9781441972194",
pages = "199--210",
booktitle = "Immunologic Signatures of Rejection",
publisher = "Springer New York",

}

TY - CHAP

T1 - D/2 predictors of favorable outcome in cancer

AU - Pós, Z.

AU - Galon, Jérôme

PY - 2011

Y1 - 2011

N2 - Prediction of disease outcome in cancer is usually achieved by histological evaluation of tissue samples obtained during surgical extirpation of the primary tumor, mostly focusing on histological characteristics of cancer cells in the tumor mass, such as the extent of atypical cell morphology, of tissue integrity, aberrant expression of protein markers or malignant transformation, senescence and proliferation, various characteristics of the invasive margin and surrounding tumor stroma, depth of invasion, and the extent of vascularization. In addition, histological or radiological analysis of both tumor draining- and distant lymph nodes and remote organs can be carried out looking for evidence of metastases. Based on these data, evaluation of cancer progression can be performed and serve as an estimate of patient prognosis. This is done on the basis of statistical data available of patients exhibiting similar progression characteristics and their actual outcome parameters, such as average disease-free (DFS), disease-specific (DSS) and overall survival (OS). To this end, several dozens of tumor-type specific staging and grading systems have been developed such as Clark's and Breslow's indexes for melanoma, Gleason's score for prostate cancer, Duke's for colorectal cancer, Boden-Gibb's staging for testicular cancer, the Evans staging system for neuroblastoma, etc., and also more universal ones such as the TNM system, which summarizes data on tumor burden (T), presence of cancer cells in draining and distant lymph nodes (N) and evidence for metastases (M). With the large body of statistical data available on cancer patients' survival with a given progression stage, such approaches have been shown to be valuable and in many cases of acceptable accuracy in estimating disease outcome in cancer.

AB - Prediction of disease outcome in cancer is usually achieved by histological evaluation of tissue samples obtained during surgical extirpation of the primary tumor, mostly focusing on histological characteristics of cancer cells in the tumor mass, such as the extent of atypical cell morphology, of tissue integrity, aberrant expression of protein markers or malignant transformation, senescence and proliferation, various characteristics of the invasive margin and surrounding tumor stroma, depth of invasion, and the extent of vascularization. In addition, histological or radiological analysis of both tumor draining- and distant lymph nodes and remote organs can be carried out looking for evidence of metastases. Based on these data, evaluation of cancer progression can be performed and serve as an estimate of patient prognosis. This is done on the basis of statistical data available of patients exhibiting similar progression characteristics and their actual outcome parameters, such as average disease-free (DFS), disease-specific (DSS) and overall survival (OS). To this end, several dozens of tumor-type specific staging and grading systems have been developed such as Clark's and Breslow's indexes for melanoma, Gleason's score for prostate cancer, Duke's for colorectal cancer, Boden-Gibb's staging for testicular cancer, the Evans staging system for neuroblastoma, etc., and also more universal ones such as the TNM system, which summarizes data on tumor burden (T), presence of cancer cells in draining and distant lymph nodes (N) and evidence for metastases (M). With the large body of statistical data available on cancer patients' survival with a given progression stage, such approaches have been shown to be valuable and in many cases of acceptable accuracy in estimating disease outcome in cancer.

UR - http://www.scopus.com/inward/record.url?scp=80052828276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052828276&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-7219-4_13

DO - 10.1007/978-1-4419-7219-4_13

M3 - Chapter

SN - 9781441972194

SN - 9781441972187

SP - 199

EP - 210

BT - Immunologic Signatures of Rejection

PB - Springer New York

ER -